Synthesis and Expression of a Gene From Kringle-2 Domain of Tissue Plasminogen Activator in E. coli

The DNA fragment corresponding to the tissue plasminogen activator (tPA) sequence 174-262 (Kringle-2 domain) has been synthesized by using the solid phase phosphotriester method. The Kringle-2 domain of human tPA was expressed in Escherichia colt by secretion into the periplasmic space using the Lpp-Lac promoter and PIN-Ⅲ OmpA2 signal sequence. About two thirds of the expression product was secreted into the periplasmic space , and purified with ammonium sulfate fractionation, affinity chro-matography on Lysine-Sepharose, and FPLC-Mono Q exchange chromatography. The amino acid composition observed from the Kringle-2 purified from E. coli is identical with that expected for the 174-262 fragment of human tPA. Radio binding assay shows that the recombinant Kringle-2 domain possesses the activity of fibrin binding.     

抗活化血小板单克隆抗体与尿激酶杂合分子的纤溶作用

用双功能团试剂将尿激酶(UK)B链和抗人活化血小板α-颗粒膜蛋白GMP-140单克隆抗体(SZ-51)的Fab片段共价偶联。偶联的杂合分子UK-SZ-51保留了原抗体的结合专一性,它在体外的溶栓效率较尿激酶提高约5倍,其溶栓作用对血浆中纤维蛋白原的含量无影响。     

THE STRUCTURE BASIS OF THE POOR FIBRIN SPECIFICITY OF UROKINASE(Ⅱ)——THE INHIBITION OF UROKINASE A CHAIN 149--157 ON THE FIBRIN STIMULATED ACTIVATION OF PLASMINOGEN BY TISSUE TYPE PLASMINOGEN ACTIVATOR

In view of the similarity of the charge distribution between fibrin A_α148--161 and Achain 149--157 of urokinase,the latter might compete with fibrin A_α148--161 when singlechain pro-urokinase is converted to double chain urokinase.To test this, the stretch of uro-kinase A chain 135--157 was separated from the low molecular weight urokinase, a competi-tive binding between this stretch and fibrin to tPA kringle-2 was shown by radio-bindingassay. The inhibition of the stretch on the fibrin stimulated activation of plasminogen wasdemonstrated in the caseinolytic system. The synthesized novapeptide urokinase A chain 149--157 (R-peptide) showed a significant inhibition on the activation of plasminogen in the pres-ence of fibrin. By contrasting finely with R-peptide, a synthesized novapeptide in which Arg154and Arg156 were replaced by Asp (D-peptide) did not show any inhibition effect on the fi-brin stimulated activation of plasminogen by tPA. These results suggest that the positivelycharged residues in the     

ROLE OF CALCIUM IN ELECTRO-ACUPUNCTURE ANALGESIA AND THE DEVELOPMENTS OF ANALGESIC TOLERANCE TO ELECTROACUPUNTURE AND MORPHINE

Role of brain Ca~(2+) in electro-acupuncture analgesia and the development of analgesic tolerance to electro-acupuncture and morphine were studied. At the same time, the inhibition by protein synthesis inhibiturs of the development of analgesic tolerance to electro-acupuncture was observed. The results showed that like morphine tolerance, the brain Ca~(2+) and cAMP levels in mice were enhanced with the development of analgesic tolerance to electro-acupuncture. After treatment with protein synthesis inhibitors anisomycin, actinomycin or cycloheximide the development of analgesic tolerance to electro-acupuncture was inhibited, and concurrently, the brain Ca~(2+) and cAMP levels in the animals greatly reduced. From the changes of brain Ca~(2+) and cAMP levels, the analgesic effects by electro-acupuncture, morphine and lanthanides seem to be very similar and share a mutual ion basis and the mechanism of action. So does the development of analgesic tolerance to electro-acupuncture and morphine. These finding     

Hybridization to an Anti-activated Platelet Monoclonal Antibody Enhances Fibrinolytic Potency on Urokinase

The B-chain of urokinase (UK) was covalently linked by disulfide bond to the Fab fragment of an anti-human activated platelet monoclonal antibody(SZ-51). The UKSZ-51 conjugate retained the original binding specificity of its parent antibody, and produced about a 5-fold enhancement in clot lysis in plasma over that of the urokinase in vitro. Whereas UK significantly decreased the concentration of fibrinogen in plasma clot assay supernatants, UK-SZ-51 did not.     

钙离子在电针镇痛、电针耐受和吗啡耐受发展中的作用

本文研究了Ca~(2+)在电针镇痛、电针耐受和吗啡耐受发展中的作用,同时了解电针耐受发展是否能被蛋白质合成抑制剂抑制。实验结果表明,和吗啡耐受一样,电针耐受动物的脑Ca~(2+)和cAMP水平均明显增高。用蛋白质合成抑制剂茴香霉素(Anisomycin)、放线菌素(Actinomycin)或环己亚胺(Cycloheximide)处理后,电针镇痛耐受发展被抑制,同时使脑Ca~(2+)和cAMP水平降低.从脑Ca~(2+)和cAMP水平的变化看,电针、吗啡和镧系元素引起的镇痛,以及电针和吗啡的耐受发展不仅相似,很可能还有共同的离子基础和作用机理,同时提示蛋白质合成抑制剂阻断电针和吗啡的耐受发展似与新的多肽或RNA合成相关。     

tPA Kringle-2结构域基因的合成及其在大肠杆菌中表达

本文用固相磷酸三酯法合成了组织型纤溶酶原激活剂(tPA)174-262片段(Kringle-2结构域)对应的DNA序列。利用PIN Ⅲ OmpA2表达质粒的信号序列和Plpp-lac启动子在大肠杆菌中表达了tPA Kringle-2。约2/3的表达产物分泌在大肠杆菌的周间质中。经硫酸铵盐析,Lysine-Sepharose亲和层析和FPLC-MONOQ离子交换层析等3步纯化后其氨基酸组成和tPA 174-262片段的组成一致。放射结合分析证明重组表达的tPA Kringle-2具有纤维蛋白结合活性。     

尿激酶对纤维蛋白低亲和性的结构基础——Ⅱ.尿激酶A链149—157片段对纤维蛋白促进tPA激活纤溶酶原的抑制作用

本文从低分子量尿激酶(LUK)中分离并纯化了UK 135—157片段,用放射结合分析证明UK 135—157片段和纤维蛋白对tPA的结合呈竞争关系。用酪蛋白降解系统证明此片段可抑制纤维蛋白促进tPA对纤溶酶原的激活。化学合成了UK149—157九肽(R-肽)以及由Asp取代Arg 154和Arg 156的相应九肽(D-肽),发现R-肽对纤维蛋白促进tPA激活纤溶酶原有显著的抑制作用,而D-肽却全无作用。本文结果证明:UK 149—157片段中的正电荷残基在抑制环饼结构域的纤维蛋白结合活性中起重要作用。